Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Soleno Therapeutics Says On Jul. 2 Received Official meeting Minutes From Type B FDA Meeting; FDA Continued To Assert That Based On Data, Additional Trial Is Necessary For NDA But Encouraged Co. To Submit Available Data

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following a recent

SLNO